MICRO-CT IMAGING OF AVASTIN-TREATED MICE WITH LS174TT TUMORS

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 目的：研究阿瓦斯丁治疗后血管正常化的假说。我们将使用带有IsoVue 370的动态微型CT来显示血流，以及使用静态微型CT和脂质体造影剂来显示肿瘤的渗透性。10年1月5日，皮埃蒙特研究中心将有12只存活肿瘤的动物被转移到杜克大学。6只小鼠接受阿瓦斯丁治疗，6只小鼠作为对照组。治疗包括5毫克/公斤的阿瓦斯丁，每两周ip一次，从1月7日星期四开始，每周四和周一进行。第一个成像日将在1月8日星期五。 4个治疗组： 1)对照脂质体，3只动物(CL) 2)对照输液，3只动物(CP) 3)经处理的脂质体，3只动物(TL) 4)治疗灌流，3只动物(TP) CL组和TL组于周一经尾静脉注射脂质造影剂(0.3ml/25g小鼠)，每周一(0小时)和周三(48小时)进行静态Micro-CT成像。CP组和TP组在周五每周进行一次动态显微CT成像，以比较血流灌注情况。对于这些研究，我们将使用尾静脉导管以0.5ml/25g小鼠的剂量传递IsoVue 370)。动物将在每次成像后恢复。我们预计未经处理的小鼠(CL、CP)将在大约17天内达到终点，从1月5日开始第0天开始处死它们。经处理的动物(TL、TP)将在大约36天内达到终点。因此，6只动物分组(CP，CP)的成像将只进行2周。对于未经治疗的动物，成像可能持续长达5周。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Aim: Study the hypothesis of vascular normalization as a result of Avastin treatment. We will use both dynamic micro-CT with a Isovue 370 to visualize perfusion and static micro-CT with a liposomal contrast agent to visualize permeability in tumors. 12 animals with viable tumors will be transfered from Piedmont Research Center to Duke on 1-5-10. 6 mice will be treated with Avastin and 6 mice will be controls. Treatment involves 5mg/kg of Avastin given IP biweekly, and will take place on: Thursdays and Mondays starting on Thursday January 7th. The first imaging day will be Friday January 8th. 4 treatment groups: 1) Control Liposome, 3 animals (CL) 2) Control Perfusion, 3 animals (CP) 3) Treated Liposome, 3 animals ( TL) 4) Treated Perfusion, 3 animals (TP) The groups CL and TL will be injected via tail vein with liposomal contrast ( 0.3 ml/25g mouse) on Mondays and static micro-CT imaging will take place on Mondays (0 hours) and Wednesdays (48hours) every week. The groups CP and TP will be imaged once per week on Fridays using dynamic micro-CT to compare perfusion. For these stusdies we will use a tail vein catheter to deliver Isovue 370 in a dose of 0.5ml/25 g mouse). Animals will be recovered after each imaging session. We expect that untreated mice (CL, CP) will reach the end point when they will need to be sacrificed in about 17 days with Day 0 starting on January 5th. The treated animals (TL, TP) will reach the endpoint in about 36 days. Therefore, imaging the 6 animals in groups (CP,CP) will take place for only 2 weeks. For untreated animals the imaging could last up to 5 weeks.